Identification | Back Directory | [Name]
2-Azetidinecarboxamide, 1-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]-, (2S)- | [CAS]
2286257-25-6 | [Synonyms]
2-Azetidinecarboxamide, 1-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]-, (2S)- | [Molecular Formula]
C18H19FN2O2 | [MOL File]
2286257-25-6.mol | [Molecular Weight]
314.35 |
Chemical Properties | Back Directory | [Boiling point ]
497.9±45.0 °C(Predicted) | [density ]
1.269±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMF: 15 mg/ml,DMSO: 2 mg/ml,Ethanol: 2 mg/ml | [form ]
A crysalline solid | [pka]
16.07±0.20(Predicted) |
Hazard Information | Back Directory | [Uses]
MAO-B-IN-33 (compound C3) is a potent, reversible and selective monoamine oxidase-B (MAO-B) inhibitor with an IC50 of 0.021 μM and 26.805 μM for MAO-B and MAO-A, respectively. The selectivity of MAO-B-IN-33 is attributed to the steric clash arising from the residue differences between Phe208 (MAO-A) and Ile199 (MAO-B). MAO-B-IN-33 inhibits cerebral MAO-B activity and alleviates MPTP (HY-15608)-induced dopaminergic neuronal loss in the mouse. MAO-B-IN-33 has the potential for Parkinson's disease research[1]. | [Biological Activity]
C3 is an inhibitor of monoamine oxidase B (MAO-B; IC50 = 0.021 μM).1 It is selective for MAO-B over MAO-A (IC50 = 26.8 μM). C3 (0.1, 1, and 3 mg/kg) prevents MPTP-induced decreases in brain dopamine levels in mice. | [IC 50]
MAO-B: 0.021 μM (IC50); MAO-A: 26.805 μM (IC50) | [storage]
-20°C | [References]
1.Jin, C.-F., Wang, Z.-Z., Chen, K.-Z., et al.Computational fragment-based design facilitates discovery of potent and selective monoamine oxidase-B (MAO-B) inhibitorJ. Med. Chem.63(23)15021-15036(2020)
|
|
|